Product Description
Candesartan is used alone or together with other medicines to treat high blood pressure (hypertension) in adults and children 1 to 16 years of age. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure can reduce the risk of strokes and heart attacks. Candesartan is also used to treat heart failure in adults and cut down on the number of hospital visits for heart problems. Candesartan is an angiotensin II receptor blocker (ARB). It works by blocking the action of a substance in the body that causes the blood vessels to tighten. As a result, candesartan relaxes the blood vessels. (Sourced from: https://www.mayoclinic.org/drugs-supplements/candesartan-oral-route/side-effects/drg-20068192?p=1)
Mechanisms of Action: AT1 Antagonist,ARB Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Cardiomyopathy, Dilated|Hypertension
Phase 2: Migraine Disorders|Migraine with Aura|Migraine without Aura
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| EARLY-GENE | P3 |
Active, not recruiting |
Cardiomyopathy, Dilated |
2026-03-09 |
|
| OPTION TREAT | P3 |
Recruiting |
Hypertension |
2023-12-31 |
|
| CandMig III | P2 |
Active, not recruiting |
Migraine with Aura|Migraine without Aura|Migraine Disorders |
2023-12-15 |